EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age‐Sex‐ H. Pylori Exposure Matched Cohort Study and Cost‐Effectiveness Analysis

Zohar Levi, Naim Abu-Freha iD, Doron Boltin iD, Maya Aharoni Golan, Tom Konikoff iD, Orly Sneh Arbib, Rachel Gingold Belfer, Sapir Eizenstein, Alex Vilkin, Shiri Kusnir, Adi Turgeman, Tanya Babich und 4 weitere

Helicobacter · 2026

DOI: 10.1111/hel.70120 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Helicobacter, 2026. Verfasst von Zohar Levi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Rabin Medical Center, Petach-Tikva, Israel. Hauptthemen laut MEDLINE: Helicobacter Infections, Stomach Neoplasms, Feces, Esophageal Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clalit Health Services, Israel Cancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims We evaluated the association between Fecal Immunochemical Test (FIT) results and the risk of gastroesophageal cancer (GEC) in a matched cohort, as well as the cost‐effectiveness of a one‐time esophagogastroduodenoscopy (EGD) for individuals who tested FIT‐positive.

Methods

We formed a cohort of individuals aged 50–75 years who underwent FIT testing at Clalit Health in Israel from 2016 to 2019. For each person with a positive FIT result, we matched three individuals with negative results by age, gender, and H. pylori exposure. We used adjusted hazard ratios (adjHRs) to assess the association between a positive FIT result and the risk of GEC within 36 months. We calculated the incremental cost‐effectiveness ratio (ICER) for a one‐time EGD costing USD 350 in individuals who tested positive for FIT, and considered it cost‐effective if below USD 50,000.

Results

The study included 150,391 individuals (47.6% female, median age 62.4 years). During follow‐up, 202 cases of GEC were recorded: 0.17% in FIT‐positive individuals (64/37,709) and 0.12% in FIT‐negative individuals (138/112,682), adjHR 1.39 (95% CI 1.03–1.87). GEC was also associated with H. pylori exposure (adjHR 1.43, 95% CI 1.08–1.90) and immigration from high‐risk countries. A one‐time EGD demonstrated favorable cost‐effectiveness across various scenarios, with an ICER of USD 25,535/QALY.

Conclusions

This matched‐cohort study suggests that individuals with a positive FIT may have an increased risk of GEC, comparable to that of established high‐risk populations. Adding a one‐time EGD to colonoscopy for FIT‐positive individuals may be a cost‐effective approach for healthcare systems that can accommodate such interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsStomach NeoplasmsFecesEsophageal NeoplasmsEarly Detection of CancerHumansMiddle AgedFemaleCost-Benefit AnalysisAgedCost-Effectiveness AnalysisMaleCohort StudiesHelicobacter pyloriIsrael

Stichwörter der Autor:innen

colorectal cancer (CRC)cost‐effectivenessfecal immunochemical testgastroesophageal cancerscreening

Autor:innen und Institutionen

  • Division of Gastroenterology, Rabin Medical Center, Petach-Tikva, Israel.
  • Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
  • Department of Gastroenterology, Soroka Medical Center, Beer Sheba, Israel.
  • Ben-Gurion University, Beer Sheba, Israel.
  • Kaplan Medical Center, Rehovot, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

ORCID-Profile: Naim Abu-Freha, Doron Boltin, Tom Konikoff, Anath A Flugelman

Förderung

  • Clalit Health Services
  • Israel Cancer Association

Zitieren

APA

Levi, Z., Abu-Freha, N., Boltin, D., Golan, M. A., Konikoff, T., Arbib, O. S., Belfer, R. G., Eizenstein, S., Vilkin, A., Kusnir, S., Turgeman, A., Babich, T., Leshno, M., Flugelman, A. A., Edelman-Klapper, H., & Half-Onn, E. (2026). The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age‐Sex‐ H. Pylori Exposure Matched Cohort Study and Cost‐Effectiveness Analysis. Helicobacter. https://doi.org/10.1111/hel.70120

Vancouver

Levi Z, Abu-Freha N, Boltin D, Golan MA, Konikoff T, Arbib OS, et al. The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age‐Sex‐ H. Pylori Exposure Matched Cohort Study and Cost‐Effectiveness Analysis. Helicobacter. 2026. doi:10.1111/hel.70120

BibTeX
@article{Levi2026,
  author = {Levi, Zohar and Abu-Freha, Naim and Boltin, Doron and Golan, Maya Aharoni and Konikoff, Tom and Arbib, Orly Sneh and Belfer, Rachel Gingold and Eizenstein, Sapir and Vilkin, Alex and Kusnir, Shiri and Turgeman, Adi and Babich, Tanya and Leshno, Moshe and Flugelman, Anath A and Edelman-Klapper, Hadar and Half-Onn, Elizabeth},
  title = {The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age‐Sex‐ H. Pylori Exposure Matched Cohort Study and Cost‐Effectiveness Analysis},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70120}
}
Kostenlos starten →